#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

News

Oko AI

Artificial Intelligence and Deep Learning as the Future of Glaucoma Diagnosis

21. 2. 2024 Source: medScope.pro

Glaucoma represents a group of eye diseases characterized by changes to the optic nerve. It is the second most common cause of blindness, currently affecting more than 90 million people worldwide. It is projected that by 2040, the number of people diagnosed with glaucoma will nearly double. According to a study published in the journal Biomedical Engineering Online in December 2023, effective screening examinations utilizing the diagnostic skills of artificial intelligence will become increasingly important in ophthalmology.

MUDr. Zárubová FOTO

MUDr. Jana Zárubová: Experiences with buccal midazolam in real practice are positive and we can significantly improve patients' quality of life

Recently, it has emerged as an alternative to traditionally rectally administered diazepam for stopping prolonged convulsive seizures in patients with epilepsy. What can buccal midazolam offer them…
21. 2. 2024 Source: Quick aid for acute convulsive seizures in children and adolescents
Epilepsie_žena

IEC 2023: Key Challenges for Epilepsy Patients Include Status Epilepticus and Anxiety Management

Why is anxiety a significant issue for epilepsy patients? What do current insights say about the connection between epilepsy and anxiety? Can artificial intelligence be used to predict status…
21. 2. 2024 Source: Quick aid for acute convulsive seizures in children and adolescents
MOZOG NEURON

Ocrelizumab in the Treatment of Multiple Sclerosis –⁠ 10-Year Data

Multiple sclerosis (MS) is a lifelong disease with a high risk of permanent disability. Current information on the long-term efficacy and safety of treatment is therefore absolutely essential for the…
20. 2. 2024 Source: Neurology - Multiple Sclerosis
symptomatická léčba

Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM

Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy of symptomatic treatment with mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), with…
19. 2. 2024 Source: Hypertrophic Cardiomyopathy (HCM)
farmakoterapie

Mavacamten in the Treatment of HCM in Patients Referred for Septal Reduction

Extended 56-week follow-up of patients with hypertrophic cardiomyopathy (HCM) resistant to current pharmacotherapy in the VALOR-HCM study confirmed the lasting benefit of mavacamten –⁠ the first…
19. 2. 2024 Source: Hypertrophic Cardiomyopathy (HCM)
starší muž aktivita

How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?

Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells with varying degrees of risk of progression to acute myeloid leukemia (AML). The therapeutic options…
15. 2. 2024 Source: Myelodysplastic Syndrome (MDS)
3D tisk

Planning Surgery Using 3D Printing in Practice –⁠ Case Study

In October 2023, an article by neurosurgeons from Leipzig University was published in the journal 3D Printing in Medicine, focusing on the use of 3D printing in the treatment of complex…
25. 1. 2024 Source: medScope.pro
trombocyty

Immunomodulation and Romiplostim −⁠ What Does the Recently Published iROM Study Say?

Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the production of antibodies but also changes in cytokine levels, predominance of Th1 lymphocytes over Th2,…
24. 1. 2024 Source: Immune Thrombocytopenia
klinickastudie

ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia

The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses…
24. 1. 2024 Source: Immune Thrombocytopenia
léčba leukemie_lékař a pacient

Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy

The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) in…
24. 1. 2024 Source: Acute Myeloid Leukemia
docSova

Doc. Milan Sova: AAT substitution is available to all indicated patients. It is therefore crucial to now educate about the necessity of regular treatment

Alpha-1-antitrypsin deficiency (AATD) is one of the most common genetic disorders in adults. It is usually associated with the early development of chronic obstructive pulmonary disease (COPD) or…
18. 1. 2024 Source: Deficiency of Alpha-1-Antitrypsin
kost_

Anabolic Antiosteoporotic Treatment as a First Step in Patients with Very High Fracture Risk

According to the 2022 opinion of the ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases) working group, it is advisable to identify…
18. 1. 2024 Source: Osteoporosis – Trends in Sequential Therapy
srdce

Cardio-renal-metabolic syndrome in context

The increase in the incidence of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and chronic kidney disease (CKD) ranks among the most significant health issues of our time. Based on recent...
16. 1. 2024 Source: Heart Failure
FOTO_Garnolová

MUDr. Petra Garnolová: The combination of medical cannabis with other analgesics is the ideal way to achieve the best effect with the fewest side effects

Medical cannabis is gradually finding its way to many patients with various ailments, including those with unmanageable and hard-to-influence chronic pain. For them, this therapy can offer a new…
8. 1. 2024 Source: Medical Cannabis
1 15 16 17 18 19 115
Filter by speciality
Remove filters

Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#